Multikinase inhibitors

What are Multikinase inhibitors?

Multikinase inhibitors work by inhibiting multiple intracellular and cell surface kinases, some of which are implicated in tumor growth and metastatic progression of cancer, thus decreasing tumor growth and replication. Multikinase inhibitors may be used to treat advanced kidney cancer as well as other specific types of cancer.

During recent years, a new treatment option with multikinase inhibitors (MKIs) such as sunitinib, sorafenib, lenvatinib, pazopanib, vandetanib, and cabozantinib has shown promising results in otherwise treatment-refractory thyroid cancer

Enzyme inhibitors can be used as drugs to inhibit chemical processes. These include Acyclovir (fighting herpes), methotrexate (fighting bacterial infections as well as cancers), Trazadone (combating depression), and ciglitazone (to address inflammatory diseases).

To date, many Type I kinase inhibitors for the treatment of cancer have been approved by the FDA viz. bosutinib, crizotinib, dasatinib, erlotinib, gefitinib, lapatinib, pazopanib, ruxolitinib, sunitinib, and vemurafenib

Approved fibroblast growth factor receptor (FGFR) inhibitors include erdafitinib, pemigatinib, and futibatinib. We review the most common toxicities associated with FGFR inhibitors and provide practical advice regarding their management.

Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

Drug	Target	Type
Erdafitinib	alpha1-acid glycoprotein	carrier
Futibatinib	Cytochrome P450 3A4	enzyme
Futibatinib	ATP-dependent translocase ABCB1	transporter
Futibatinib	Broad substrate specificity ATP-binding cassette transporter ABCG2	transporter